Marken announced that it has significantly upgraded its existing operating system with a centralized web-based software exclusively designed for its growing supply chain organization. The system, known as ‘Maestro’ has a flexible architecture which will enable extensive tracking of shipments, integrated documentation, client reporting, and performance monitoring. It is designed explicitly for ease of integration with client’s systems to meet their growing requirements with temperature and time sensitive drugs to be shipped worldwide. Its interfaces and flexible structure enables each of its clients to input and track relevant data connected with a clinical trial and manage the hand-offs between shipments from site to lab and country to country. This new operating system, when coupled with Marken’s new Solo™ system for its depot operations, will allow Marken to manage the complete inbound and outbound cycle for clinical trials.
“We are very proud to announce the new Maestro system to our clients”, said Cyril Leger, Chief Operating Officer, Marken LLC. “We have been working on this new system for many months and have incorporated our best thinking as well as feedback from our clients. Our customer service representatives can now work more efficiently around the clock, across all of our 24 branch locations, and track shipments more precisely than ever before”.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.